市場調查報告書
商品編碼
991651

乾眼症 (DED)的全球市場 - 各疾病、治療、終端用戶、流通管道、地區、國家分析 (2021年版):市場考察、COVID-19的影響、競爭、預測 (2021∼2026年)

Global Dry Eye Disease (DED) Market - Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid -19 Impact, Competition and Forecast (2021-2026)

出版日期: | 出版商: Azoth Analytics | 英文 226 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球乾眼症 (DED)的市場規模,2020年是53億7859萬美金。

乾眼症(DED)據報導是尋求醫療眼睛保健的最常見原因,醫院的門診病人診療所或檢眼診療的到院患者每5人有1人經歷乾眼症。平均壽命的上升,人口的高齡化,勞動人口增加,螢幕看太久,及各種生活方式的變化,DED的經濟

本報告提供全球乾眼症 (DED) 市場相關調查,各市場區隔,及各地區的市場分析與預測,競爭情形分析,主要企業簡介等資訊。

目錄

第1章 調查範圍和調查手法

  • 調查範圍
  • 調查手法
  • 摘要整理

第2章 策略建議

第3章 全球乾眼症 (DED) 市場:產品展望

第4章 全球乾眼症 (DED) 市場:市場規模、預測

第5章 全球乾眼症 (DED) 市場區隔:各疾病、治療、終端用戶、流通管道

  • 全球乾眼症疾病市場競爭模式:各疾病
    • 淚液分泌減少型乾眼症市場規模、預測
    • 淚液汽化亢進型市場規模、預測
    • 其他的市場規模、預測
  • 全球乾眼症疾病市場競爭模式:各治療
    • 眼科用藥市場規模、預測
    • 抗發炎藥市場規模、預測
    • 其他的市場規模、預測
  • 全球乾眼症疾病市場競爭模式:各終端用戶
    • 家庭醫療保健市場規模、預測
    • 診所市場規模、預測
    • 醫院市場規模、預測
    • 其他市場規模、預測
  • 全球乾眼症疾病市場競爭模式:各流通管道
    • 醫院藥局市場規模、預測
    • 零售業者市場規模、預測
    • 線上市場規模、預測
    • 其他的市場規模、預測

第6章 全球乾眼症 (DED) 市場:地區分析

第7章 北美的乾眼症 (DED) 市場:各疾病、治療、終端用戶、流通管道 (以金額為準)

  • 北美的市場規模、預測 (以金額為準)
  • 北美市場:主要企業
  • 市場區隔:各疾病
  • 市場區隔:各治療
  • 市場區隔:各終端用戶
  • 市場區隔:各流通管道
  • 北美市場:各國分析
  • 北美市場機會表:各國 (以金額為準)
  • 北美市場競爭模式:各國
  • 美國的市場規模、預測 (以金額為準)
  • 美國的主要企業
  • 美國市場區隔::疾病、治療、終端用戶、各流通管道
  • 加拿大的市場規模、預測 (以金額為準)
  • 加拿大市場區隔::疾病、治療、終端用戶、各流通管道

第8章 歐洲的乾眼症 (DED) 市場:形狀、各終端用戶 (以金額為準、以數量為準)

  • 歐洲的市場規模、預測 (以金額為準)
  • 歐洲市場:主要企業
  • 市場區隔:各疾病
  • 市場區隔:各治療
  • 市場區隔:各終端用戶
  • 市場區隔:各流通管道
  • 歐洲市場:各國分析
  • 歐洲市場機會表:各國 (以金額為準)
  • 歐洲市場競爭模式:各國
  • 德國
  • 法國
  • 英國
  • 義大利

第9章 亞太地區的乾眼症 (DED) 市場:形狀、各終端用戶 (以金額為準、以數量為準)

  • 亞太地區的市場規模、預測 (以金額為準)
  • 亞太地區市場:主要企業
  • 市場區隔:各疾病
  • 市場區隔:各治療
  • 市場區隔:各終端用戶
  • 市場區隔:各流通管道
  • 亞太地區市場:各國分析
  • 亞太地區市場機會表:各國 (以金額為準)
  • 亞太地區市場競爭模式:各國
  • 中國
  • 日本
  • 印度
  • 韓國

第10章 全球乾眼症 (DED) 市場動態

  • 全球市場的促進因素
  • 全球市場的阻礙因素
  • 世界市場趨勢

第11章 市場魅力、策略性分析

  • 市場魅力
    • 全球市場魅力表:各疾病
    • 全球市場魅力性表:各治療
    • 全球市場魅力性表:各終端用戶
    • 全球市場魅力性表:各流通管道
    • 全球市場魅力表:各地區
  • 策略性分析
    • 最新的技術創新和M&A
    • 市場佔有率分析

第12章 企業簡介概要(營業內容,財務分析,事業策略)

  • Johnson & Johnson
  • Bausch Health
  • Alcon
  • Allergan PLC
  • Novartis AG
  • Santen Pharmaceuticals Co. Ltd
  • VISUfarma
  • Horus Pharma
  • Novaliq GmbH
  • Sentiss Pharma Pvt Ltd
目錄

Executive Summary

Global Dry Eye Disease Market, valued at USD 5378.59 Million in the year 2020, affects tens of millions of individuals around the world, and both its frequency and impact increase with age. Consequently, it is considered a major international health concern. Dry eye is the most commonly reported reason for seeking medical eye care, and up to one in five patients presenting to hospital outpatient clinics or optometry practices experience dry eye. With increased life expectancy, aging population, increasing number of working population, excess time spend using screens, and various lifestyle changes, the economic and social impacts of DED are expected to grow substantially in the coming years, which has been anticipated to infuse growth in the market for Dry Eye Disease during the forecast period of 2021-2026.

Under the Disease segment, Evaporative Dry Eye Disease are anticipated to witness the largest market share owing to recent clinical and epidemiological studies confirming that most dry eye patients show signs of mixed evaporative and aqueous deficient dry eye, with evaporative dry eye being the most common manifestation. Evaporative dry eye is most often associated with meibomian gland dysfunction (MGD) that will be pushing growth in the market for Dry Eye Disease during the coming years.

Hospitals, followed by Clinics attained substantial market share under End User segment, chiefly on the back of growing number of people suffering from eye disorders supported by manufacturers spending heavily on creating awareness among people regarding variety of eye disorders and their consequences, and investing in expanding their manufacturing capacity in order to cater to rising demand for eye care products, which will spur the market growth for dry eye care products in the coming years.

Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable market share owing to presence of various leading global manufacturers in the region with companies ramping up their production capacity with escalating number of people suffering from dry disease owing to excess time spent over screens supported by investment in expanding product portfolio by manufacturers to offer various types of Dry Eye Disease products to users. These factors will be accelerating the market growth during the forecast period.

Scope of the Report

  • The report analyses Dry Eye Disease market By Value.
  • The report analyses Dry Eye Disease Market By Disease (Aqueous, Evaporative, Others).
  • The report assesses the Dry Eye Disease market By Treatment (Eye Drops, Anti-Inflammatory Drugs, Others).
  • The report further segments the market By End User (Home Healthcare, Clinics, Hospitals, and Others) and By Distribution Channel (Hospital Pharmacies, Retailers, Online, Others).
  • The Global Dry Eye Disease Market has been analysed By Region (North America, Europe, Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Italy, China, Japan, India, South Korea).
  • The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Technological Innovations, and Role of Manufacturers during Covid-19 pandemic.
  • Also, the attractiveness of the market has been presented By Region, Disease, Treatment, End User, and Distribution Channel. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The companies analysed in the report include Johnson & Johnson, Bausch Health, Alcon, Allergan PLC, Novartis AG, Santen Pharmaceuticals Co. Ltd, VISUfarma, Horus Pharma, Novaliq GmbH, Sentiss Pharma Pvt Ltd..
  • The report presents the analysis of Dry Eye Disease market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience

  • Dry Eye Disease Products Manufacturers
  • Hospitals, Clinics, and Healthcare Units
  • Pharmacies, and Retailers
  • Consulting and Advisory Firms
  • Investment Banks and Equity Firms

Table of Contents

1. Report Scope and Methodology

  • 1.1 Research Methodology
  • 1.2 Executive Summary

2. Strategic Recommendations

3. Dry Eye Disease Market Product Outlook

4. Global Dry Eye Disease Market: Sizing and Forecast

5. Global Dry Eye Disease Market Segmentation By Disease, By Treatment, By End User, By Distribution Channel

  • 5.1 Competitive Scenario of Global Dry Eye Disease Market: By Disease
    • 5.1.1 Aqueous n Market Size and Forecast (2016-2026)
    • 5.1.2 Evaporative n Market Size and Forecast (2016-2026)
    • 5.1.3 Others n Market Size and Forecast (2016-2026)
  • 5.2 Competitive Scenario of Global Dry Eye Disease Market: By Treatment
    • 5.2.1 Eye Drops n Market Size and Forecast (2016-2026)
    • 5.2.2 Anti-Inflammatory Drugs n Market Size and Forecast (2016-2026)
    • 5.2.3 Others n Market Size and Forecast (2016-2026)
  • 5.3 Competitive Scenario of Global Dry Eye Disease Market: By End User
    • 5.3.1 Home Healthcare n Market Size and Forecast (2016-2026)
    • 5.3.2 Clinics n Market Size and Forecast (2016-2026)
    • 5.3.3 Hospitals n Market Size and Forecast (2016-2026)
    • 5.3.4 Others n Market Size and Forecast (2016-2026)
  • 5.4 Competitive Scenario of Global Dry Eye Disease Market: By Distribution Channel
    • 5.4.1 Hospital Pharmacies n Market Size and Forecast (2016-2026)
    • 5.4.2 Retailers n Market Size and Forecast (2016-2026)
    • 5.4.3 Online n Market Size and Forecast (2016-2026)
    • 5.4.4 Others n Market Size and Forecast (2016-2026)

6. Global Dry Eye Disease Market: Regional Analysis

7. North America Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value))

  • 7.1 North America Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 7.2 North America Dry Eye Disease Market n Prominent Companies
  • 7.3 Market Segmentation by Disease (Aqueous, Evaporative, and Others)
  • 7.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, and Others)
  • 7.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, and Others)
  • 7.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)
  • 7.7 North America Dry Eye Disease Market: Country Analysis
  • 7.8 Market Opportunity Chart of North America Dry Eye Disease Market n By Country, By Value (Year 2026)
  • 7.9 Competitive Scenario of North America n By Country
  • 7.10 United States Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 7.11 United States Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
  • 7.12 Canada Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 7.13 Canada Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)

8. Europe Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value))

  • 8.1 Europe Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 8.2 Europe Dry Eye Disease Market n Prominent Companies
  • 8.3 Market Segmentation by Disease (Aqueous, Evaporative, Others)
  • 8.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, Others)
  • 8.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, Others)
  • 8.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)
  • 8.7 Europe Dry Eye Disease Market: Country Analysis
  • 8.8 Market Opportunity Chart of Europe Dry Eye Disease Market - By Country, By Value (Year 2026)
  • 8.9 Competitive Scenario of Europe n By Country
  • 8.10 Germany Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 8.11 Germany Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
  • 8.12 France Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 8.13 France Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)
  • 8.14 United Kingdom Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 8.15 United Kingdom Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
  • 8.16 Italy Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 8.17 Italy Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)

9. Asia Pacific Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021n2026) (By Value))

  • 9.1 Asia Pacific Dry Eye Disease Market: Size and Forecast (2021n2026), By Value
  • 9.2 Asia Pacific Dry Eye Disease Market n Prominent Companies
  • 9.3 Market Segmentation by Disease (Aqueous, Evaporative, and Others)
  • 9.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, Others)
  • 9.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, Others)
  • 9.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)
  • 9.7 Asia Pacific Dry Eye Disease Market: Country Analysis
  • 9.8 Market Opportunity Chart of Asia Pacific Dry Eye Disease Market n By Country, By Value (Year 2026)
  • 9.9 Competitive Scenario of Asia Pacific By Country
  • 9.10 China (Mainland China, Hong Kong, Macau, and Taiwan) Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 9.11 China (Mainland China, Hong Kong, Macau, and Taiwan) Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
  • 9.12 Japan Dry Eye Disease Market: Size and Forecast (2021-2026) By Value
  • 9.13 Japan (Mainland China, Hong Kong, Macau, and Taiwan) Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)
  • 9.14 India Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 9.15 India Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
  • 9.16 South Korea Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
  • 9.17 South Korea Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)

10. Global Dry Eye Disease Market Dynamics

  • 10.1 Global Dry Eye Disease Market Drivers
  • 10.2 Global Dry Eye Disease Market Restraints
  • 10.3 Global Dry Eye Disease Market Trends

11. Market Attractiveness and Strategic Analysis

  • 11.1 Market Attractiveness
    • 11.1.1 Market Attractiveness Chart of Global Dry Eye Disease Market - By Disease, By Value (Year 2026)
    • 11.1.2 Market Attractiveness Chart of Global Dry Eye Disease Market - By Treatment, By Value (Year 2026)
    • 11.1.3 Market Attractiveness Chart of Global Dry Eye Disease Market - By End User, By Value (Year 2026)
    • 11.1.4 Market Attractiveness Chart of Global Dry Eye Disease Market - By Distribution Channel, By Value (Year 2026)
    • 11.1.5 Market Attractiveness Chart of Global Dry Eye Disease Market - By Region, By Value (Year 2026)
  • 11.2 Strategic Analysis
    • 11.2.1 Latest Technological Innovations and Mergers & Acquisitions
    • 11.2.2 Market Share Analysis

12. Company Profiles (Business Description, Financial Analysis, Business Strategy)

  • 12.1 Johnson & Johnson
  • 12.2 Bausch Health
  • 12.3 Alcon
  • 12.4 Allergan PLC
  • 12.5 Novartis AG
  • 12.6 Santen Pharmaceuticals Co. Ltd
  • 12.7 VISUfarma
  • 12.8 Horus Pharma
  • 12.9 Novaliq GmbH
  • 12.10 Sentiss Pharma Pvt Ltd

List of Figures

  • Figure 1: Global Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 2: Global Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 3: Global Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 4: Global Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 5: Global Prevalence of Cataract, 2015-2019 (In %)
  • Figure 6: Global Population, By End User Group, 2020 (In Millions)
  • Figure 7: Global Total Population, By End User 15n64 Years, 2015-2019 (In Billion)
  • Figure 8: Global Total Population, By End User 0n14 Years, 2015-2019 (In Billions)
  • Figure 9: Segmental Analysis, By Disease, 2020, 2026
  • Figure 10: Global Dry Eye Disease Market n By Aqueous, By Value (USD Million), 2016-2026
  • Figure 11: Global Dry Eye Disease Market n By Evaporative, By Value (USD Million), 2016-2026
  • Figure 12: Global Dry Eye Disease Market n By Others, By Value (USD Million), 2016-2026
  • Figure 13: Segment Analysis by Treatment, 2020, 2026
  • Figure 14: Global Dry Eye Disease Market n By Eye Drops, By Value (USD Million), 2016-2026
  • Figure 15: Global Dry Eye Disease Market n By Anti-Inflammatory Drugs, By Value (USD Million), 2016-2026
  • Figure 16: Global Dry Eye Disease Market n By Others, By Value (USD Million), 2016-2026
  • Figure 17: Segmental Analysis, By End User, 2020, 2026
  • Figure 18: Global Dry Eye Disease Market n By Home Healthcare, By Value (USD Million), 2016-2026
  • Figure 19: Global Dry Eye Disease Market n By Clinics, By Value (USD Million), 2016-2026
  • Figure 20: Global Dry Eye Disease Market n By Hospitals, By Value (USD Million), 2016-2026
  • Figure 21: Global Dry Eye Disease Market n By Others, By Value (USD Million), 2016-2026
  • Figure 22: Segment Analysis by Distribution Channel, 2020, 2026
  • Figure 23: Global Dry Eye Disease Market n By Hospital Pharmacies, By Value (USD Million), 2016-2026
  • Figure 24: Global Dry Eye Disease Market n By Retailers, By Value (USD Million), 2016-2026
  • Figure 25: Global Dry Eye Disease Market n By Online, By Value (USD Million), 2016-2026
  • Figure 26: Global Dry Eye Disease Market n By Others, By Value (USD Million), 2016-2026
  • Figure 27: Segment Analysis by Region, 2020, 2026
  • Figure 28: North America Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 29: North America Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 30: North America Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 31: North America Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 32: North America Prevalence of Cataract, 2015-2019 (In %)
  • Figure 33: North America Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 34: North America Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 35: North America Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 36: North America Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 37: Market Opportunity Chart of North America Dry Eye Disease Market n By Country, By Value, 2026
  • Figure 38: Segment Analysis by Country, 2020, 2026
  • Figure 39: United States Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 40: United States Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 41: United States Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 42: United States Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 43: United States Prevalence of Cataract, 2015-2019 (In %)
  • Figure 44: United States Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 45: United States Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 46: United States Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 47: United States Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 48: Canada Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 49: Canada Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 50: Canada Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 51: Canada Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 52: Canada Prevalence of Cataract, 2015-2019 (In %)
  • Figure 53: Canada Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 54: Canada Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 55: Canada Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 56: Canada Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 57: Europe Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 58: Europe Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 59: Europe Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 60: Europe Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 61: Europe Prevalence of Cataract, 2015-2019 (In %)
  • Figure 62: Europe Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 63: Europe Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 64: Europe Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 65: Europe Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 66: Market Opportunity Chart of Europe Dry Eye Disease Market n By Country, By Value, 2026
  • Figure 67: Europe Dry Eye Disease Market, By Country, 2020, 2026
  • Figure 68: Germany Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 69: Germany Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 70: Germany Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 71: Germany Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 72: Germany Prevalence of Cataract, 2015-2019 (In %)
  • Figure 73: Germany Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 74: Germany Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 75: Germany Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 76: Germany Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 77: France Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 78: France Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 79: France Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 80: France Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 81: France Prevalence of Cataract, 2015-2019 (In %)
  • Figure 82: France Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 83: France Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 84: France Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 85: France Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 86: United Kingdom Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 87: United Kingdom Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 88: United Kingdom Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 89: United Kingdom Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 90: United Kingdom Prevalence of Cataract, 2015-2019 (In %)
  • Figure 91: United Kingdom Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 92: United Kingdom Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 93: United Kingdom Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 94: United Kingdom Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 95: Italy Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 96: Italy Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 97: Italy Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 98: Italy Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 99: Italy Prevalence of Cataract, 2015-2019 (In %)
  • Figure 100: Italy Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 101: Italy Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 102: Italy Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 103: Italy Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 104: Asia Pacific Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 105: Asia Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 106: Asia Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 107: Asia Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 108: Asia Prevalence of Cataract, 2015-2019 (In %)
  • Figure 109: Asia Pacific Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 110: Asia Pacific Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 111: Asia Pacific Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 112: Asia Pacific Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 113: Market Opportunity Chart of Asia Pacific Dry Eye Disease Market By Country, By Value, 2026
  • Figure 114: Asia Pacific Dry Eye Disease Market, By Country, 2020, 2026
  • Figure 115: China Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 116: China Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 117: China Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 118: China Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 119: China Prevalence of Cataract, 2015-2019 (In %)
  • Figure 120: China Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 121: China Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 122: China Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 123: China Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 124: Japan Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 125: Japan Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 126: Japan Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 127: Japan Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 128: Japan Prevalence of Cataract, 2015-2019 (In %)
  • Figure 129: Japan Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 130: Japan Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 131: Japan Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 132: Japan Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 133: India Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 134: India Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 135: India Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 136: India Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 137: India Prevalence of Cataract, 2015-2019 (In %)
  • Figure 138: India Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 139: India Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 140: India Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 141: India Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 142: South Korea Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
  • Figure 143: South Korea Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
  • Figure 144: South Korea Prevalence of Glaucoma, 2015-2019 (In %)
  • Figure 145: South Korea Prevalence of Refraction Disorders, 2015-2019 (In %)
  • Figure 146: South Korea Prevalence of Cataract, 2015-2019 (In %)
  • Figure 147: South Korea Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
  • Figure 148: South Korea Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
  • Figure 149: South Korea Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
  • Figure 150: South Korea Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
  • Figure 151: Market Attractiveness Chart of Global Dry Eye Disease Market n By Disease, 2026
  • Figure 152: Market Attractiveness Chart of Global Dry Eye Disease Market By Treatment, 2026
  • Figure 153: Market Attractiveness Chart of Global Dry Eye Disease Market By End User, 2026
  • Figure 154: Market Attractiveness Chart of Global Dry Eye Disease Market By Distribution Channel, 2026
  • Figure 155: Market Attractiveness Chart of Global Dry Eye Disease Market By Region, 2026
  • Figure 156: Market Share of Leading Global Dry Eye Disease Companies, 2020 (In %)
  • Figure 157: Johnson & Johnson Revenue, 2015-2019 (In USD Billion)
  • Figure 158: Johnson & Johnson Net Revenue, By Business Segment, 2018 (In %)
  • Figure 159: Johnson & Johnson Net Revenue, By Business Segment, 2019 (In %)
  • Figure 160: Johnson & Johnson Net Revenue, By Geographic Segment, 2018 (In %)
  • Figure 161: Johnson & Johnson Net Revenue, By Geographic Segment, 2019 (In %)
  • Figure 162: Johnson & Johnson, Net Sales, By Medical Devices, 2018 (In %)
  • Figure 163: Johnson & Johnson, Net Sales, By Vision Segment, 2018 (In %)
  • Figure 164: Bausch Health Revenue, 2015-2019 (In USD Billion)
  • Figure 165: Bausch Health Net Revenue, By Business Segment, 2018 (In %)
  • Figure 166: Bausch Health Net Revenue, By Business Segment, 2019 (In %)
  • Figure 167: Bausch Health Net Revenue, By Geographic Segment, 2018 (In %)
  • Figure 168: Bausch Health Net Revenue, By Geographic Segment, 2019 (In %)
  • Figure 169: Alcon Revenue, 2015-2019 (In USD Billion)
  • Figure 170: Alcon Net Revenue, By Business Segment, 2018 (In %)
  • Figure 171: Alcon Net Revenue, By Business Segment, 2019 (In %)
  • Figure 172: Alcon Revenue, Business Segment, 2018, 2019 (In USD Billion)
  • Figure 173: Alcon Net Revenue, By Geographic Segment, 2018 (In %)
  • Figure 174: Alcon Net Revenue, By Geographic Segment, 2019 (In %)
  • Figure 175: Allergan PLC Revenue, 2014-2018 (In USD Billion)
  • Figure 176: Allergan PLC Net Revenue, By Business Segment, 2017 (In %)
  • Figure 177: Allergan PLC Net Revenue, By Business Segment, 2018 (In %)
  • Figure 178: Allergan PLC Net Revenue, By Geographic Segment, 2017 (In %)
  • Figure 179: Allergan PLC Net Revenue, By Geographic Segment, 2018 (In %)
  • Figure 180: Novartis AG Revenue, 2015-2019 (In USD Billion)
  • Figure 181: Novartis AG Net Revenue, By Business Segment, 2018 (In %)
  • Figure 182: Novartis AG Net Revenue, By Business Segment, 2019 (In %)
  • Figure 183: Santen Pharmaceutical Co. Ltd. Revenue, 2015-2019 (In USD Billion)
  • Figure 184: Santen Pharmaceutical Co. Ltd. Revenue, By Business Segment, 2018 (In %)
  • Figure 185: Santen Pharmaceutical Co. Ltd. Revenue, By Business Segment, 2019 (In %)
  • Figure 186: Santen Pharmaceutical Co. Ltd. Net Revenue, By Geographic Segment, 2018 (In %)
  • Figure 187: Santen Pharmaceutical Co. Ltd. Net Revenue, By Geographic Segment, 2019 (In %)